Search research articles
Contact Us
Filters
Showing results (41-50 of 103) with videos related to
Page
of 11
Sort By:
American Journal of Hematology
|
December 30, 2025
Extramedullary Disease-Achilles Heel in Myeloma?
Shaji Kumar, Joshua Richter, Saad Z Usmani, et al.
Blood
|
October 27, 2012
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter, Natalia Neparidze, Lin Zhang, et al.
Advances in Hematology
|
December 29, 2025
Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns
Csaba Siffel, Matthew S Davids, Colin Anderson-Smits, et al.
Therapeutic Advances in Hematology
|
February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 11, 2024
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Joshua Richter, Matthew S Davids, Colin Anderson-Smits, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 16, 2024
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Noopur S Raje, Adam D Cohen, Krina K Patel, et al.
Expert Review of Hematology
|
August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
Larysa Sanchez, Kevin Barley, Joshua Richter, et al.
Cancer Treatment Reviews
|
February 6, 2025
Diagnosis and management of bispecific T cell-engaging antibody toxicity: A primer for emergency physicians
Monica K Wattana, Jonathan Rowland, Aiham Qdaisat, et al.
Bone Marrow Transplantation
|
May 19, 2019
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
Noa Biran, Scott D Rowley, David H Vesole, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 103) with videos related to
Sort By:
Page
of 11
American Journal of Hematology
|
December 30, 2025
Extramedullary Disease-Achilles Heel in Myeloma?
Shaji Kumar, Joshua Richter, Saad Z Usmani, et al.
Blood
|
October 27, 2012
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter, Natalia Neparidze, Lin Zhang, et al.
Advances in Hematology
|
December 29, 2025
Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns
Csaba Siffel, Matthew S Davids, Colin Anderson-Smits, et al.
Therapeutic Advances in Hematology
|
February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 11, 2024
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Joshua Richter, Matthew S Davids, Colin Anderson-Smits, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 16, 2024
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Noopur S Raje, Adam D Cohen, Krina K Patel, et al.
Expert Review of Hematology
|
August 1, 2020
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
Larysa Sanchez, Kevin Barley, Joshua Richter, et al.
Cancer Treatment Reviews
|
February 6, 2025
Diagnosis and management of bispecific T cell-engaging antibody toxicity: A primer for emergency physicians
Monica K Wattana, Jonathan Rowland, Aiham Qdaisat, et al.
Bone Marrow Transplantation
|
May 19, 2019
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
Noa Biran, Scott D Rowley, David H Vesole, et al.
Page
of 11